Glucose Health (GLUC) vs. Its Competitors Head-To-Head Contrast

Glucose Health (OTCMKTS:GLUC) is one of 51 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its rivals? We will compare Glucose Health to similar companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, risk, dividends and earnings.

Profitability

This table compares Glucose Health and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	-75.00%	N/A	N/A
Glucose Health Competitors	-42.21%	-22.72%	-7.72%

Analyst Recommendations

This is a summary of current ratings and target prices for Glucose Health and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	N/A
Glucose Health Competitors	272	537	980	74	2.46

As a group, “Medicinals & botanicals” companies have a potential upside of 62.07%. Given Glucose Health’s rivals higher probable upside, analysts plainly believe Glucose Health has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Glucose Health and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Glucose Health	$540,000.00	-$420,000.00	-8.67
Glucose Health Competitors	$303.26 million	-$49.38 million	-8.57

Glucose Health’s rivals have higher revenue, but lower earnings than Glucose Health. Glucose Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

16.2% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 21.6% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Glucose Health has a beta of 3.49, indicating that its share price is 249% more volatile than the S&P 500. Comparatively, Glucose Health’s rivals have a beta of 1.07, indicating that their average share price is 7% more volatile than the S&P 500.

Summary

Glucose Health rivals beat Glucose Health on 6 of the 10 factors compared.

Glucose Health Company Profile

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.